Raia Drogasil SA (RADLY)
4.99
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
Raia Drogasil Enterprise Value: 9.057B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 9.057B |
| May 30, 2024 | 9.057B |
| May 29, 2024 | 9.057B |
| May 28, 2024 | 10.21B |
| May 24, 2024 | 10.21B |
| May 23, 2024 | 10.21B |
| May 22, 2024 | 10.21B |
| May 21, 2024 | 8.903B |
| May 20, 2024 | 8.903B |
| May 17, 2024 | 8.903B |
| May 16, 2024 | 9.932B |
| May 15, 2024 | 8.800B |
| May 14, 2024 | 9.469B |
| May 13, 2024 | 9.469B |
| May 10, 2024 | 9.074B |
| May 09, 2024 | 9.074B |
| May 08, 2024 | 9.074B |
| May 07, 2024 | 9.074B |
| May 06, 2024 | 9.074B |
| May 03, 2024 | 9.074B |
| May 02, 2024 | 9.074B |
| May 01, 2024 | 9.074B |
| April 30, 2024 | 9.074B |
| April 29, 2024 | 9.074B |
| April 26, 2024 | 9.074B |
| Date | Value |
|---|---|
| April 25, 2024 | 9.091B |
| April 24, 2024 | 9.897B |
| April 23, 2024 | 10.63B |
| April 22, 2024 | 9.091B |
| April 19, 2024 | 9.074B |
| April 18, 2024 | 9.074B |
| April 17, 2024 | 9.074B |
| April 16, 2024 | 9.074B |
| April 15, 2024 | 10.62B |
| April 12, 2024 | 10.62B |
| April 11, 2024 | 10.62B |
| April 10, 2024 | 9.125B |
| April 09, 2024 | 9.125B |
| April 08, 2024 | 9.125B |
| April 05, 2024 | 9.125B |
| April 04, 2024 | 9.125B |
| April 03, 2024 | 9.125B |
| April 02, 2024 | 9.125B |
| April 01, 2024 | 9.125B |
| March 31, 2024 | 9.125B |
| March 28, 2024 | 9.198B |
| March 27, 2024 | 9.764B |
| March 26, 2024 | 9.764B |
| March 25, 2024 | 9.764B |
| March 22, 2024 | 10.28B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
5.134B
Minimum
Mar 30 2020
52.86B
Maximum
Feb 27 2023
8.527B
Average
8.165B
Median
Enterprise Value Benchmarks
| Hypera SA | 4.707B |
| CEL-SCI Corp | 60.22M |
| AIM ImmunoTech Inc | 10.88M |
| IGC Pharma Inc | 29.80M |
| NovaBay Pharmaceuticals Inc | 4.387M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 37.93M |
| Revenue (Quarterly) | 1.838B |
| Total Expenses (Quarterly) | 1.732B |
| EPS Diluted (Quarterly) | 0.0227 |
| Gross Profit Margin (Quarterly) | 29.22% |
| Profit Margin (Quarterly) | 2.06% |
| Earnings Yield | 2.53% |
| Operating Earnings Yield | 4.91% |
| Normalized Earnings Yield | 2.148 |